Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Factorial trial of carbamazepine, levetiracetam, or active monitoring with or without sleep behavior intervention in children with rolandic epilepsy
2018-003893-29Phase 4Terminated
- Sponsor
- King's College London
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of carbamazepine and levetiracetam in Benign Rolandic Epilepsy (BECTS) (6 arms), sponsored by King's College London. Primary endpoint: Time to six-month seizure remission. Started Oct 2019; status: terminated.
02
Drugs
carbamazepinelevetiracetam
03
Conditions
Benign Rolandic Epilepsy (BECTS)
Beyond the preview
Go deeper on 2018-003893-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003893-29.